KarenAnneAutioMD

PubMed

• Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.
  Chen, N., McGrath, C., Ericsson, C., Vaselkiv, J., Rencsok, E., Stopsack, K., Guard, H., Autio, K., Rathkopf, D., Enting, D., Bitting, R., Mateo, J., Githiaka, C., Chi...> ;Cancer Epidemiology, Biomarkers & Prevention. 2024 Mar 1
• A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer.
  Dorff, T., Horvath, L., Autio, K., Bernard-Tessier, A., Rettig, M., Machiels, J., Bilen, M., Lolkema, M., Adra, N., Rottey, S., Greil, R., Matsubara, N., Tan, D., Wong...> ;Clinical Cancer Research. 2024 Feb 1
• Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States.
  Rencsok, E., Slopen, N., McManus, H., Autio, K., Morgans, A., McSwain, L., Barata, P., Cheng, H., Dreicer, R., Gerke, T., Green, R., Heath, E., Howard, L., McKay, R., ...> ;Cancer Research Communications. 2024 Jan 8
• Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.
  de Almeida, D., Cohn, E., Baser, R., Anderson, J., Danila, D., Morris, M., Slovin, S., Abida, W., Scher, H., Autio, K.> ;Journal of Immunotherapy and Precision Oncology. 2023 Nov 1
• 1 citations
  Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US.
  Emily M Rencsok, Natalie Slopen, Karen Autio, Alicia Morgans, Lawrence McSwain, Pedro Barata, Heather H Cheng, Robert Dreicer, Elisabeth Heath, Rana R McKay, Mark Pome...> ;Quality of Life Research. 2023 Nov 1
• 1 citations
  Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients.
  Kelsey E Breen, Heather Symecko, Kelsey Spielman, Rebecca Gebert, Ibrahim H Shah, Stacy Pundock, Melissa Batson, Vivek K Narayan, Zsofia K Stadler, Karen A Autio, Wass...> ;The Journal of Urology. 2023 May 1
• 4 citations
  First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
  Sophie Postel-Vinay, Vincent K Lam, Willeke Ros, Todd M Bauer, Aaron R Hansen, Daniel C Cho, F Stephen Hodi, Jan H M Schellens, Jennifer K Litton, Sandrine Aspeslagh, ...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
• 2 citations
  First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic c...
  Karen A Autio, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Tian Zhang, Xin-Hua Zhu, Hani Babiker, Nicholas J Vogelzang, Sandip M Prasad, Michael T Schweizer...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
• 8 citations
  Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
  Hong Truong, Kelsey Breen, Subhiksha Nandakumar, Daniel D Sjoberg, Yelena Kemel, Nikita Mehta, Andrew T Lenis, Peter A Reisz, Jessica Carruthers, Nicole Benfante, Vija...> ;European Urology. 2023 Jan 1
• Oligometastatic Squamous Cell Transformation From Metastatic Prostate Adenocarcinoma Treated With Systemic and Focal Therapy: A Case Report.
  Karen Autio, Sean McBride> ;Journal of Immunotherapy and Precision Oncology. 2022 Aug 1
• 3 citations
  Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.
  Niamh M Keegan, Samantha E Vasselman, Ethan S Barnett, Barbara Nweji, Emily A Carbone, Alexander Blum, Michael J Morris, Dana E Rathkopf, Susan F Slovin, Daniel C Dani...> ;The Prostate. 2022 Aug 1
• 3 citations
  Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prosta...
  Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth I. Heath,...> ;European Urology Open Science. 2021 Dec 1
• 25 citations
  Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors
  Konrad H. Stopsack, Subhiksha Nandakumar, Kanika Arora, Bastien Nguyen, Samantha E. Vasselman, Barbara Nweji, Sean McBride, Michael J. Morris, Dana E. Rathkopf, Susan ...> ;Clinical Cancer Research. 2021 Oct 19
• 15 citations
  CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding...
  Rachel E. Sanborn, Omid Hamid, Elisabeth G.E. de Vries, Patrick A. Ott, Javier Garcia-Corbacho, Valentina Boni, Johanna C. Bendell, Karen A. Autio, Daniel C. Cho, Ruth...> ;Journal for Immunotherapy of Cancer. 2021 Jul 1
• 22 citations
  CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
  Aung Naing, Fiona C Thistlethwaite, Elisabeth G.E. de Vries, Ferry A.L.M. Eskens, Nataliya Uboha, Patrick A. Ott, Patricia LoRusso, Javier Garcia-Corbacho, Valentina B...> ;Journal for Immunotherapy of Cancer. 2021 Jul 1
• 22 citations
  Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors.
  Kyriakos P. Papadopoulos, Karen A. Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Qiusheng Chen, Richard Wnek, Georgina V. Long> ;Clinical Cancer Research. 2021 Apr 1
• 8 citations
  Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
  J. Randolph Hecht, Kyriakos P. Papadopoulos, Gerald Steven Falchook, Manish R. Patel, Jeffrey R. Infante, Raid Aljumaily, Deborah J. Wong, Karen A. Autio, Zev A. Wainb...> ;Investigational New Drugs. 2021 Feb 1
• 27 citations
  Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
  Karen A. Autio, Christopher A. Klebanoff, David Schaer, John S. Kauh, Susan F. Slovin, Matthew Adamow, Victoria S. Blinder, Manisha Brahmachary, Michelle Carlsen, Eliz...> ;Clinical Cancer Research. 2020 Aug 26
• 16 citations
  Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
  Daniel Vargas Pivato de Almeida, Lawrence Fong, Matthew Rettig, Karen A. Autio> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2020 Apr 28
• 80 citations
  Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology.
  Karen A. Autio, Valentina Boni, R. Humphrey, Aung Naing> ;Clinical Cancer Research. 2020 Mar 1
• 69 citations
  Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
  Aung Naing, Deborah J. Wong, Jeffrey R. Infante, W. Michael Korn, Raid Aljumaily, Kyriakos P. Papadopoulos, Karen A. Autio, Shubham Pant, Todd M. Bauer, Alexandra Drak...> ;The Lancet. Oncology. 2019 Nov 1
• 29 citations
  Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics.
  Karen A. Autio, Martin Oft> ;Current Oncology Reports. 2019 Feb 21
• 144 citations
  PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8 + T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.
  Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Ivan H. Chan, Cong Shen, Navneet Ratti, Bianca Rojo, Karen A. Autio, Deborah J. Wong, Manish R. Patel, Patric...> ;Cancer Cell. 2018 Nov 12
• 126 citations
  Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cance...
  Karen A. Autio, Robert Dreicer, Justine Anderson, Jorge A. Garcia, Ajjai Alva, Lowell L. Hart, Matthew I. Milowsky, Edwin M. Posadas, Charles J. Ryan, Ryon P. Graf, Ry...> ;JAMA Oncology. 2018 Oct 1
• 140 citations
  Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
  Aung Naing, Kyriakos P. Papadopoulos, Karen A. Autio, Patrick A. Ott, Manish R. Patel, Deborah J. Wong, Gerald S. Falchook, Shubham Pant, Melinda Whiteside, Drew R. Ra...> ;Journal of Clinical Oncology. 2016 Oct 23
• Join now to see all

Lectures

• Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), o... 
  2019 ASCO Annual Meeting - 6/1/2019
• Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resista... 
  2019 ASCO Annual Meeting - 6/1/2019
• Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced so... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Join now to see all